Clinical Trial Update: A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells [Phase 1]

View source ↗

Summary

Phase 1 trial in healthy, HIV-1-uninfected adults compared the safety, tolerability, and immunogenicity of CH505TF gp120 produced from stably transfected cells …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CH505TF gp120 (produced from stably transfected cells)
• CH505TF gp120 (produced from transiently transfected cells)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2022-07-11